G6PD Deficiency: Causes, Symptoms, Diagnosis and Treatment


◉ Causes

One or more mutations for G6PD deficiency with exposure to certain agents like:

◉ Risk factors

◉ Symptoms and Signs

Most G6PD deficiency sufferers go their entire lives without showing any symptoms, and they are completely unaware of their condition, that is, until they are exposed to a drug or chemical (like fava beans), which causes RBC hemolysis 24 to 72 hours after exposure.

◉ Complications

◉ Diagnosis and Screening

History and physical exam findings, such as severe anemia coexisting with hemoglobinuria following consumption of fava beans or a potentially hemolytic medication, strongly imply the diagnosis of G6PD deficiency.

After the acute hemolytic crisis has passed (2 3 weeks after the acute hemolytic event), additional testing for a particular disease is necessary if the history, physical examination, and blood cell count results are indicative of G6PD deficiency.

Diagnostic screening begins with quick semiquantitative testing. Quantitative evaluation of the overall percentage of G6PD enzymatic activity is done after the confirmatory test, which is the gold standard.

◉ Treatment

The objectives of treatment are to manage by ceasing the precipitating agent or treating the underlying clinical condition that is causing the oxidative stress, prevent hemolysis by educating patients and avoiding triggers, treat infant hyperbilirubinemia brought on by a G6PD deficiency as well as any necessary anemia.

Criteria for admission

Criteria for ICU admission

Recommendations for specialist referral

Stop using the precipitating agent or address the underlying medical issue that led to oxidative stress and subsequent hemolysis. The majority of the time, acute hemolysis brought on by G6PD deficiency is transient and does not need to be treated. Rarely do young toddlers and newborns need to get RBC transfusions in response to an acute hemolytic episode.

For hyperbilirubinemia, newborns could need phototherapy or an exchange transfusion. To prevent kernicterus and irreparable brain impairment, hyperbilirubinemia in the newborn period must be promptly managed.

Patients with nonspherocytic hemolytic anemia or chronic hemolysis may benefit from folic acid therapy.

◉ Conclusion

Despite the fact that G6PD is the most prevalent enzyme deficiency illness, the majority of patients with the diagnosis do not experience any symptoms, and those who do only experience brief symptoms with few or no problems. G6PD has the advantage of being largely avoidable.


Sources

  1. Cappellini MD, Fiorelli G. Glucose 6 phosphate dehydrogenase deficiency. The lancet. 2008;371(9606):64 74.
  2. Nkhoma ET, Poole C, Vannappagari V, et al. The global prevalence of glucose 6 phosphate dehydrogenase deficiency: a systematic review and meta analysis. Blood Cells, Molecules, and Diseases. 2009;42(3):267 78.
  3. Frank JE. Diagnosis and management of G6PD deficiency. American family physician. 2005;72(7):1277 82.
  4. Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859.